BCM
STLN

Basso Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Basso Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-145,485
Closed -$1.46M – 189
2020
Q2 		$1.46M Buy
+145,485
New +$1.45M 0.46% 68

Other funds holding STLN

UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Basso Capital Management's STLN Position: Q3 2020 in Review

Basso Capital Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q3 2020, closing a stake of 145,485 shares — an estimated $1.46M sold.

Basso Capital Management first reported a position in STLN in Q2 2020 and held it in 1 quarter. The position peaked at $1.46M in Q2 2020. 38 funds tracked by Wall St. Rank hold STLN as of Q3 2020.

  • Basso Capital Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Basso Capital Management sold 145,485 Starling Oncology Institute, Inc. Common Stock shares in Q3 2020, an estimated $1.46M.
  • Basso Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Basso Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $1.46M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2020.

Based on Basso Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.